<DOC>
	<DOCNO>NCT01331616</DOCNO>
	<brief_summary>Does treatment bevacizumab ( Avastin ) combination prior current radiotherapy lead optic neuropathy ?</brief_summary>
	<brief_title>Optic Neuropathy 10 Patients With Glioblastoma Receiving Bevacizumab</brief_title>
	<detailed_description>The investigator research focus patient prior begin treatment bevacizumab ( Avastin ) , undergo baseline visual examination Visual evoke Potentials test . This allow test patient 's optic nerve function bilaterally . Patients begin normally schedule treatment avastin , chemotherapeutic agent , well radiation treatment schedule . Once patient complete treatment avastin 6-8 week , undergo second Visual Evoked Potential testing , study compare change within optic nerve . Patients also recommend stringent follow Ophthalmologist include confrontational visual field testing , external anterior segment examination , dilate fundus examination . The investigator main objective ass whether bevacizumab cause direct toxic effect patient 's optic nerve lead acute/subacute optic neuropathy .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Diagnosed w Glioblastoma grade IV , schedule begin chemo radiotherapy Avastin No diagnosis GBM , schedule begin treatment avastin combination radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Prospective study</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Avastin</keyword>
	<keyword>Visual Evoked Potential</keyword>
	<keyword>Optic neuropathy</keyword>
	<keyword>Chemo-radiotherapy</keyword>
</DOC>